Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Journal of Vascular and Interventional Radiology

Volumn 23, Issue 7, 2012, Pages 927-936

  Park, Won Hyeong ^a   Shim, Ju Hyun ^a   Han, Seung Bong ^a   Won, Hyung Jin ^a   Shin, Yong Moon ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Lee, Han Chu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DECARBOXYPROTHROMBIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOLOGY; REPEAT PROCEDURE; SEROLOGY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ENDPOINT DETERMINATION; FEMALE; HEMOSTATICS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PROTEIN PRECURSORS; PROTHROMBIN; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84862836324     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.04.021     Document Type: Article

References (42)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022.
2. Salem R, Riaz A, Memon K, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation. J Hepatol 2011; 54:695-704.
3. Arnold MM, Kreel L, Wallace AC, Li AK. Distribution of Lipiodol and evidence for tumor necrosis in hepatocellular carcinoma. Am J Clin Pathol 1992; 97:405-410.
4. Gillmore R, Stuart S, Kirkwood A, et al. EASL And mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011; 55: 1309-1316.
5. Riaz A, Lewandowski RJ, Kulik L, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 2010; 33:1143-1152.
6. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062-1069.
7. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5:145-159. (Pubitemid 32118643)
8. Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin. Liver Int 2011; 31:22-35.
9. Saito M, Seo Y, Yano Y, Miki A, Yoshida M, Azuma T. A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. J Gastroenterol 2012, 10.1007/s00535-012-0577-0.
10. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446-452.
11. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27: 5734-5742.
12. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432-438.
13. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12:1175-1181.
14. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37:1114-1121. (Pubitemid 36538688)
15. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. alpha-fetoprotein in nonneoplastic hepatic disorders. JAMA 1975; 233:38-41.
16. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. Serum alphafetoprotein in patients with massive hepatic necrosis. Gastroenterology 1977; 72:479-492.
17. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010; 55:2744-2755.
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
19. Shim JH, Kim KM, Lee YJ, et al. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol 2010; 17:869-877.
20. Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 1992; 182:709-713.
21. Bargellini I, Vignali C, Cioni R, et al. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria - selection parameter for liver transplantation. Radiology 2010; 255:289-300.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
23. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008; 26:3913-3915.
24. Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88:1557-1564. (Pubitemid 30183140)
25. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62(suppl 1):57- 63.
26. Nakao A, Suzuki Y, Isshiki K, et al. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol 1991; 86:62-66.
27. Aoyagi Y, Oguro M, Yanagi M, et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77:1781-1786. (Pubitemid 26125176)
28. Shimada M, Takenaka K, Fujiwara Y, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78:2094-2100. (Pubitemid 26367601)
29. Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010; 45:1272-1282.
30. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-417. (Pubitemid 34810361)
31. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alphafetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16:2795-2804.
32. Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91:561-569. (Pubitemid 32105702)
33. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:532-540.
34. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97:1042-1050. (Pubitemid 36173156)
35. Herber S, Biesterfeld S, Franz U, et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31:768-777.
36. Imaeda T, Yamawaki Y, Seki M, et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 1993; 16:209-213. (Pubitemid 23204501)
37. Guan YS, Sun L, Zhou XP, Li X, Zheng XH. Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 2004; 10:3543-3548. (Pubitemid 39619265)
38. Kim HC, Kim AY, Han JK, et al. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 2002; 225:773-780. (Pubitemid 35387116)
39. Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N. Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 2009; 20:30-38.
40. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82:1643-1648. (Pubitemid 28208912)
41. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101:2038-2043. (Pubitemid 44337629)
42. Altman DG, Bland JM. Diagnostic tests. 1: sensitivity and specificity. Br Med J 1994; 308:1552.